A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected
patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Treatments:
HIV Protease Inhibitors Protease Inhibitors Saquinavir